Show simple item record

dc.contributor.authorAnandappa, G
dc.contributor.authorChau, I
dc.date.accessioned2018-02-16T09:31:56Z
dc.date.issued2017-06
dc.identifier.citationHematology/oncology clinics of North America, 2017, 31 (3), pp. 529 - 544
dc.identifier.issn0889-8588
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/1163
dc.identifier.eissn1558-1977
dc.identifier.doi10.1016/j.hoc.2017.02.001
dc.description.abstractWith further understanding of the biology of gastric and gastroesophageal adenocarcinomas, strides are being made to find effective treatments through novel trial designs. This article focuses on the ongoing trials of drugs targeting specific hallmarks of gastric and gastroesophageal cancers, including oncogene addiction proliferative pathways (fibroblast growth factor receptor 2 amplified tumors), stem cell inhibition, apoptotic induction through claudin inhibitors, and matrix metalloproteinase inhibition. In developing novel therapeutics in treatment of patients with gastroesophageal adenocarcinomas, parallel research efforts to refine target population and biomarkers are crucial, and targeting the tumor genomics and microenvironment may be key in improving overall survival.
dc.formatPrint-Electronic
dc.format.extent529 - 544
dc.languageeng
dc.language.isoeng
dc.subjectHumans
dc.subjectAdenocarcinoma
dc.subjectEsophageal Neoplasms
dc.subjectStomach Neoplasms
dc.subjectGelatinases
dc.subjectNeoplasm Proteins
dc.subjectAntineoplastic Agents
dc.subjectGene Amplification
dc.subjectReceptor, Fibroblast Growth Factor, Type 2
dc.subjectNeoplastic Stem Cells
dc.subjectClaudins
dc.titleEmerging Novel Therapeutic Agents in the Treatment of Patients with Gastroesophageal and Gastric Adenocarcinoma.
dc.typeJournal Article
rioxxterms.versionofrecord10.1016/j.hoc.2017.02.001
rioxxterms.licenseref.startdate2017-06
rioxxterms.typeJournal Article/Review
dc.relation.isPartOfHematology/oncology clinics of North America
pubs.issue3
pubs.notesNot known
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/Royal Marsden Clinical Units
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/Royal Marsden Clinical Units
pubs.publication-statusPublished
pubs.volume31
pubs.embargo.termsNot known
dc.contributor.icrauthorChau, Ianen
dc.contributor.icrauthorMarsden,en


Files in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record